Mirikizumab – the first anti-IL23 p19 antibody in ulcerative colitis therapy

Česká verze

Authors: M. Lukáš
Authors place of work: Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Published in the journal: Gastroent Hepatol 2024; 78(1): 27-30
Category: IBD
doi: https://doi.org/10.48096/ccgh202427

Zdroje

1. Lukáš M, Ďuricová D. Zkušenosti s biologickou léčbou v Klinickém centru ISCARE. In: Idiopatické střevní záněty. Nové trendy a mezioborové souvislosti. Praha: Grada Publishing 2021: 177–199.

2. Schett G, McInnes I, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med 2021; 385(7): 628–639. doi: 10.1056/ NEJMra1909 094.

3. Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double blind, randomised, placebo controlled and ustekinumab controlled phase 3 trials. Lancet 2018; 392(10148): 650–661. doi: 10.1016/ S0140-6736(18) 31713-6.

4. Peyrin-Biroulet L. Results from Sequence study. 31. UEGW 14.–17. 10. 2023, Copenhagen (přednáška).

5. Sandborn WJ, Ferrante M, Bhandari BR et al. Efficacy and safety of mirikizumab in a randomized phase 2 of patients with ulcerative colitis. Gastroenterology 2020; 158(3): 537–549. doi: 10.1053/ j.gastro.2019.08.043.

6. Sandborn WJ, Ferrante M, Bhandari BR et al. Efficacy and safety of continued treatment with mirikizumab in phase 2 trial of patients with ulcerative colitis. Clin Gastro Hepatol 2022; 20(1): 105–115. doi: 10.1016/ j.cgh.2020.09. 028.

7. D’Haens G, Dubinsky M, Kobayashi T et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2023; 388(26): 2444–2455. doi: 10.1056/ NEJMoa2207 940.

8. Navabi S, D’Haens G, Samaan K et al. Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderate to severe active ulcerative colitis. UEG Journal 2023; 11(8): 47–48.

9. Sands BE, D’Haens G, Clemow DB et al. Two year efficacy and safety of mirikizumab following 104 weeks of continuous treatment: Interim results of Lucent-3 open label extension study. Am J Gastro 2023; 11(8): 848.

10. Dubinsky M, Clemow DB, Hunter Gibble T et al. Clinical effect of mirikizumab treatment on bowel urgency in patients with moderately to severely ulcerative colitis and clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis 360 2022; 5(1): otac044. doi: 10.1093/ crocol/ otac044.

11. Travis S, Potts Blaekman A, Dubinsky MC et al. The Communicating Needs and Features of IBD Experiences CONFIDE study): UC and European patient and health care professional perceptions of the experience and impact of symptoms of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis 2023; izad142. doi: 10.1093/ ibd/ izad142.

prof. MU Dr. Milan Lukáš, CSc., AGAF
Klinické a výzkumné centrum pro střevní záněty
Klinické centrum ISCARE a.s. a 1. LF UK v Praze
Českomoravská 19
190 00 Praha 9
milan.lukas@email.cz